Across TCGA pan-cancer cohorts, IGLV2-23 mass-spec protein differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of IGLV2-23’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where IGLV2-23 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types IGLV2-23 is over-expressed in tumor, although a few such as HNSC and LUAD show the opposite, repressed pattern.

HNSC, PDAC, and LUAD are the cancer types where IGLV2-23 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in IGLV2-23 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Male	II,III,IV	−0.824	.001	8	view →
PDAC	Female	All	+1.185	.006	4	view →
LUAD	All	All	−0.555	.003	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: IGLV2-23 RNA expression & survival · all IGLV2-23 data types